RPE Cell Differentiation from Pluripotent Stem Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for producing retinal pigment epithelium (RPE) cells for therapeutic use face challenges such as limited availability, contamination risks, genetic defects, age-related issues, and immunological responses, making it difficult to treat conditions like choroideremia, diabetic retinopathy, macular degeneration, and retinitis pigmentosa effectively.

Innovation Solution

A method for differentiating RPE cells from pluripotent stem cells, involving culturing pluripotent stem cells to form embryoid bodies, selecting and propagating RPE cells in specific media supplemented with growth factors, to produce large numbers of purified, functional RPE cells that can be used therapeutically.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If RPE cells are obtained from human donors or fetal tissue, then immediate therapeutic availability is achieved, but contamination risks, genetic defects, and limited availability occur

Engineering Contradiction:

Improvetherapeutic availabilityVSAvoidcontamination risks

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent creates copies of RPE cells through in vitro differentiation of pluripotent stem cells, producing genetically identical functional cells that can be expanded indefinitely without contamination risks associated with donor-derived cells

Inventive Principle:

Principle #26Copying

Solution Approach 2:

Pluripotent stem cells serve as an intermediary source, allowing controlled differentiation into RPE cells under sterile laboratory conditions, thereby eliminating direct contamination risks from human donor tissues while maintaining cell functionality

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If RPE cells are obtained from human donors, then immediate therapeutic use is possible, but immunological rejection responses occur

Engineering Contradiction:

Improvetherapeutic useVSAvoidimmunological responses

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent produces copies of RPE cells from patient-specific or universally compatible pluripotent stem cell lines, enabling immunological matching through genetic engineering or selection of HLA-matched cell lines, thereby reducing rejection responses

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent modifies immunological parameters by engineering pluripotent stem cells to express specific HLA antigens or suppress immune recognition markers, allowing the differentiated RPE cells to evade immunological detection and rejection

Inventive Principle:

Principle #35Parameter changes

3Quantity of substance

If RPE cells are obtained from fetal tissue, then cell source availability is achieved, but age-related issues and limited proliferative potential occur

Engineering Contradiction:

Improvecell source availabilityVSAvoidproliferative potential

Core Design Contradiction:

Quantity of substanceVSDuration of action of moving object

Solution Approach 1:

The patent uses pluripotent stem cells as a universal source that can differentiate into RPE cells with extended proliferative capacity, overcoming the age-related limitations of fetal tissue while maintaining differentiation potential

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent employs culture conditions that promote excessive proliferation of pluripotent stem cells before differentiation, generating large expanses of young, healthy RPE cells that exceed the limited proliferative potential of fetal-derived cells

Inventive Principle:

Principle #16Partial or excessive action

4Productivity

If conventional RPE cell production methods are used, then cell production is achieved, but manufacturing precision and purity are insufficient

Engineering Contradiction:

Improvecell productionVSAvoidcell purity

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The patent segments the differentiation process into distinct stages with specific culture conditions and selection markers, allowing systematic purification of RPE cells from other cell types while maintaining high productivity through controlled expansion at each stage

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent implements feedback mechanisms through regular monitoring of cell markers, morphology, and differentiation markers, enabling real-time adjustment of culture conditions to maintain high RPE cell purity and prevent contamination during production

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS20240307436A2Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

Publication Date: 2024.09.19 ADVANCED CELL TECH INC

AI summary

The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.